Head-To-Head Survey: Galmed Pharmaceuticals (NASDAQ:GLMD) & JanOne (NASDAQ:JAN)

JanOne (NASDAQ:JAN) and Galmed Pharmaceuticals (NASDAQ:GLMD) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, institutional ownership and earnings.

Risk & Volatility

JanOne has a beta of 2.33, suggesting that its share price is 133% more volatile than the S&P 500. Comparatively, Galmed Pharmaceuticals has a beta of 0.87, suggesting that its share price is 13% less volatile than the S&P 500.

Profitability

This table compares JanOne and Galmed Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
JanOne	N/A	-177.90%	-55.98%
Galmed Pharmaceuticals	N/A	-53.29%	-44.35%

Analyst Ratings

This is a summary of recent recommendations and price targets for JanOne and Galmed Pharmaceuticals, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
JanOne	0	0	0	0	N/A
Galmed Pharmaceuticals	0	0	1	0	3.00

Institutional and Insider Ownership

6.3% of JanOne shares are held by institutional investors. Comparatively, 76.1% of Galmed Pharmaceuticals shares are held by institutional investors. 3.0% of JanOne shares are held by insiders. Comparatively, 19.8% of Galmed Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Valuation & Earnings

This table compares JanOne and Galmed Pharmaceuticals’ top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
JanOne	$39.61 million	0.83	-$7.81 million	N/A	N/A
Galmed Pharmaceuticals	N/A	N/A	-$6.91 million	($3.26)	-0.11

Galmed Pharmaceuticals has lower revenue, but higher earnings than JanOne.

Summary

Galmed Pharmaceuticals beats JanOne on 6 of the 8 factors compared between the two stocks.

About JanOne

JanOne Inc., a clinical-stage biopharmaceutical company, focuses on identifying, acquiring, licensing, developing, partnering, and commercializing novel, non-opioid, and non-addictive therapies to address the unmet medical need for the treatment of pain and addiction. It operates through Biotechnology and Recycling segments. The company's lead product candidate is JAN101, a patented oral and sustained release pharmaceutical composition of sodium nitrite that targets poor blood flow to the extremities in patients with diabetes or peripheral artery disease to treat pain. It also provides turnkey appliance recycling and replacement services for utilities and other sponsors of energy efficiency programs. The company was formerly known as Appliance Recycling Centers of America, Inc. and changed its name to JanOne Inc. in September 2019. JanOne Inc. was founded in 1976 and is headquartered in Las Vegas, Nevada.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd., a biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases. It develops Aramchol, an oral therapy, which is in Phase III study for the treatment of non-alcoholic steato-hepatitis (NASH) in patients with overweight or obesity and who are pre-diabetic or type-II-diabetes mellitus. The company also evaluates Aramchol through ARRIVE Study, a Phase IIa clinical trial with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. In addition, it engages in the development of Amilo-5MER, a 5 amino acid synthetic peptide methionine, threonine, alanine, aspartic acid, and valine. It has a license agreement with Samil Pharma. Co., Ltd. for the commercialization of Aramchol in the Republic of Korea; and a collaboration agreement with OnKai for its AI platform. Galmed Pharmaceuticals Ltd. was founded in 2000 and is headquartered in Tel Aviv, Israel.